Long‑term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer

Einama,Takahiro; Abe,Hironori; Shichi,Shunsuke; Matsui,Hiroki; Kanazawa,Ryo; Shibuya,Kazuaki; Suzuki,Takashi; Matsuzawa,Fumihiko; Hashimoto,Taku; Kohei,Nakachi; Homma,Shigenori; Kawamura,Hideki; Taketomi,Akinobu

doi:10.3892/mco.2017.1128

Long‑term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer

Authors:
- Takahiro Einama
- Hironori Abe
- Shunsuke Shichi
- Hiroki Matsui
- Ryo Kanazawa
- Kazuaki Shibuya
- Takashi Suzuki
- Fumihiko Matsuzawa
- Taku Hashimoto
- Nakachi Kohei
- Shigenori Homma
- Hideki Kawamura
- Akinobu Taketomi
View Affiliations

Affiliations: Department of Surgery, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Hokkaido 080‑0805, Japan, Department of Internal Gastroenterology, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Hokkaido 080‑0805, Japan, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan
Published online on: January 10, 2017 https://doi.org/10.3892/mco.2017.1128
Pages: 163-166
Copyright: © Einama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In gastric cancer, primary systemic chemotherapy is the standard approach for the management of patients with initially unresectable metastasis, and it occasionally leads to a reduction in the size of the lesion, which facilitates surgical resection. The aim of this study was to examine the prognosis of patients who were able to undergo complete resection following chemotherapy. A total of 10 patients who underwent radical surgery for stage IV primary gastric cancer after chemotherapy between 2009 and 2015 at the Department of Surgery of Hokkaido Social Work Association Obihiro Hospital (Obihiro, Japan) were retrospectively investigated. Three regimens were used (S‑1, n=1; S‑1 + cisplatin, n=8; and S‑1 + docetaxel, n=1). The mean time from chemotherapy to surgery was 210 days. One total gastrectomy + splenectomy + colectomy, one total gastrectomy + splenectomy, four total gastrectomies and three distal gastrectomies were performed. There were two cases of pancreatic fistula formation postoperatively. All the patients survived for >1 year. Of the 10 patients, 5 survived without recurrence. The median survival time was 871.1 days after diagnosis. Therefore, curative resection after chemotherapy is associated with a better prognosis in stage IV gastric cancer patients.

View Figures

View References

1	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
2	Sano T and Aiko T: New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points. Gastric Cancer. 14:97–100. 2011. View Article : Google Scholar : PubMed/NCBI
3	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
4	Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 12:3402–3407. 2006. View Article : Google Scholar : PubMed/NCBI
5	Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol. 140:319–328. 2014. View Article : Google Scholar : PubMed/NCBI
6	Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K and Ohdan H: Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: A retrospective analysis. World J Surg Oncol. 8:402010. View Article : Google Scholar : PubMed/NCBI
7	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
8	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
9	Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, Tanabe K and Suzuki T: The roles of surgical oncologists in the new era: Minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology. 78:343–352. 2011. View Article : Google Scholar : PubMed/NCBI
10	Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K and Ohdan H: Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 1:743–727. 2010.PubMed/NCBI
11	Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, Tsuji A, Sakabayashi S, Fukushima M and Sakai Y: Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer. 15:61–69. 2012. View Article : Google Scholar : PubMed/NCBI
12	Han DS, Suh YS, Kong SH, Lee HJ, Im SA, Bang YJ, Kim WH and Yang HK: Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. 107:511–516. 2013. View Article : Google Scholar : PubMed/NCBI
13	Okabe H, Ueda S, Obama K, Hosogi H and Sakai Y: Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 16:3227–3236. 2009. View Article : Google Scholar : PubMed/NCBI
14	Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, Fukushima M, Takabayashi A and Sakai Y: Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 9:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
15	Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am. 9:853–878. 2000.PubMed/NCBI
16	Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am. 82:1075–1090, x-xi. 2002. View Article : Google Scholar : PubMed/NCBI
17	Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K and Curley SA: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 239:818–827. 2004. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Yu YY, Li W, Feng Y, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Qin XY and Liu TS: A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 73:1155–1161. 2014. View Article : Google Scholar : PubMed/NCBI
19	Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, Kojima H, Matsui T, Kondo K and Fujiwara M: Long-term follow up of patients who were positive for peritoneal lavage cytology: Final report from the CCOG0301 study. Gastric Cancer. 15:335–337. 2012. View Article : Google Scholar : PubMed/NCBI
20	Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H and Mochiki E: Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol. 22:3618–3624. 2015. View Article : Google Scholar : PubMed/NCBI
21	Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol. 24:3939–3945. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ako E, Ohira M, Yamashita Y, Kubo N, Muguruma K, Yashiro M, Sawada T, Nakata B, Kato Y and Hirakawa K: Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology. Hepatogastroenterology. 55:1939–1942. 2008.PubMed/NCBI